References
Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016;43:1896–909.
Zlotta AR, Schulman CC. Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet. 2001;357:326–7. Commentary.
Deguchi T, Yang M, Ehara H, Ito S, Nishino Y, Takahashi Y, et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer. 1997;75:634–8.
US Food and Drug Administration. FDA Public Workshop on Clinical Trial Endpoints in Prostate Cancer, 21–22 June 2004. Silver Spring, MD: US Food and Drug Administration. http://www.fda.gov/ cancer drug approval endpoints
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.
Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;9:1084–6.
Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52:1721–6.
Kuroda I. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med. 2014;28:11–6.
Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41–5.
Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J Nucl Med. 1993;34:1839–44.
Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1023–30.
Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(1):171–8.
Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336–41.
Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79–86.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
M.F. is a medical advisor to CIS bio GmbH Germany, responsible only for pharmacovigilance and medical information. He has received financial support to attend workshops and scientific meetings from Amgen, Bayer, GE Healthcare, IBA Molecular. H.J.B. is a senior advisor to Tasly (Hong Kong), Shanghai, China
Rights and permissions
About this article
Cite this article
Fischer, M., Biersack, H.J. Radionuclide therapy of malignant bone lesions. Eur J Nucl Med Mol Imaging 44, 728–729 (2017). https://doi.org/10.1007/s00259-016-3574-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-016-3574-3